Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antidepressant

or Tryptamine

or [[:Category:Hormone_replacement|Hormone replacement]]

Use the filters below to narrow your results.

None (1) · 5-HT2A agonist (15) · 5-HT2A agonist; 5-HT3 antagonist (1) · 5-HT2A agonist; minor psilocybin mushroom alkaloid (1) · 5-HT2A agonist; primarily auditory effects (1) · 5-HT2A agonist; sigma-1 agonist (1) · Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Potent 5-HT2A agonist; sigma-1 agonist (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug of 4-HO-DET; 5-HT2A agonist (1) · Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) · Prodrug of 4-HO-MET; 5-HT2A agonist (1) · Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) · Prodrug of psilocin; 5-HT2A agonist (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · Synthetic T4 (thyroxine); peripherally deiodinated to T3 (triiodothyronine), the active hormone. '"`UNIQ--vote-00000031-QINU`"' Narrow therapeutic index; brand-to-generic switches can shift TSH and require re-titration'"`UNIQ--ref-00000032-QINU`"'. (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1) · '"`UNIQ--vote-00000032-QINU`"' Brand-to-brand and lot-to-lot variability in T3:T4 ratio is greater than with synthetic levothyroxine, which is why endocrine guidelines prefer the synthetic'"`UNIQ--ref-00000033-QINU`"'. (1)

None (44) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · '"`UNIQ--vote-00000033-QINU`"', '"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"' (1) · '"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"' (1) · '"`UNIQ--vote-0000149A-QINU`"', '"`UNIQ--vote-0000149B-QINU`"', '"`UNIQ--vote-0000149C-QINU`"' (1)

None (44) · 1.6 mcg/kg/d in young healthy adults; 25-50 mcg/d in elderly or cardiac disease, titrated by TSH at 6-8 weeks (1) · 25 mg (1) · 30 mg PO daily (1/2 grain); titrate by TSH at 6-8 weeks; 60 mg desiccated thyroid is approximately equivalent to 88-100 mcg levothyroxine (1) · Hypothyroidism: 5-25 mcg PO daily (start low, titrate slowly); myxedema coma: 5-20 mcg IV q4-12h with T4 loading (1)

None (44) · 15, 30, 60, 90, 120, 180, 240, 300 mg tablets (1/4 to 5 grains; 1 grain = 60 mg) (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 mcg tablets; oral capsule and IV/IM also available (1) · 5, 25, 50 mcg tablets (Cytomel); 10 mcg/mL IV (Triostat) (1)

None (44) · 100 mcg/d typical (1) · 200 mg/d (1) · No fixed maximum; titrated to TSH target (2)

None (43) · IV (2) · Oral (5)

None (43) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Hours (faster than T4); peak biologic activity 24-48 hours (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · TSH normalization 4-8 weeks (1) · TSH normalization 4-8 weeks; symptomatic improvement weeks to months (1)

None (43) · 24-72 hours (1) · Chronic daily dosing (1) · Long (1) · Steady-state at 4-6 weeks (2)

None (43) · T4 ~7 days; T3 ~1 day'"`UNIQ--ref-00000036-QINU`"' (1) · ~1 day (much shorter than T4's ~7 days)'"`UNIQ--ref-0000149D-QINU`"' (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~7 days (euthyroid); longer in hypothyroidism (~9-10 days), shorter in hyperthyroidism'"`UNIQ--ref-00000036-QINU`"' (1)

None (43) · 40-80% (oral); reduced by food, calcium, iron, PPIs, fiber; take fasting with water'"`UNIQ--ref-00000037-QINU`"' (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Variable; reduced by food, calcium, iron, PPIs'"`UNIQ--ref-00000037-QINU`"' (1) · ~50% (highly variable) (1) · ~95% (oral)'"`UNIQ--ref-0000149E-QINU`"' (1)

None (43) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · First-line in pregnancy; dose typically increased 25-30% due to estrogen-driven rise in TBG and fetal demand. Lactation safe at physiologic doses.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Synthetic levothyroxine is the standard-of-care in pregnancy; desiccated thyroid use in pregnancy is not well studied[[[Pharmacopedia:Citation needed|citation needed]]] (1) · T4 (levothyroxine) is the first-line in pregnancy; T3 is rarely needed.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

None (43) · Rx-only (1) · Rx-only in US (1) · [[USLegal:Prescription only|Rx-only]] in US (3)